Dydrogesterone Should NOT Be Used as a Tocolytic
Dydrogesterone is not recommended for tocolytic use at any gestational age, as current evidence does not support its efficacy in preventing preterm birth or improving maternal and neonatal outcomes.
Evidence Base
The available evidence clearly demonstrates that dydrogesterone lacks proven efficacy as a tocolytic agent:
Research Findings
A 2026 systematic review and meta-analysis 1 found no statistically significant benefit of oral dydrogesterone compared to placebo for preventing preterm birth. The certainty of evidence was rated as low to very low using GRADE methodology, and trial sequential analysis confirmed the evidence base remains underpowered and insufficient for clinical recommendations.
A 2021 randomized controlled trial 2 evaluated oral dydrogesterone (10 mg three times daily) in women with preterm labor at 24-34 weeks gestation. The study found no difference in latency period (27.5 days vs 34 days, p=0.45), gestational age at delivery, or rates of preterm delivery before 34 or 37 weeks compared to placebo.
Guideline Evidence on Progestogens for Tocolysis
The 2012 AJOG guideline 3 explicitly addresses progestogens for tocolysis and states: "there is currently insufficient evidence to recommend progestogens for primary, adjunctive, or maintenance tocolysis." This applies to all progestogen formulations, including dydrogesterone.
Important Distinctions
Do not confuse tocolysis with preterm birth prevention:
- 17-hydroxyprogesterone caproate (17OHP-C) is recommended for women with singleton pregnancy and prior spontaneous preterm birth, administered from 16-20 weeks until 36 weeks 4
- This is for prevention, not acute tocolysis
- Dydrogesterone is not equivalent to 17OHP-C and lacks this evidence base
Safety Concerns
Recent pharmacovigilance data 5 from VigiBase showed increased reporting of birth defects, particularly hypospadias and congenital heart defects, associated with dydrogesterone exposure during early pregnancy (ROR 5.4,95% CI [3.7-7.9] compared to progesterone). While causality requires further investigation, this raises additional concerns about its use.
Clinical Bottom Line
Dydrogesterone should not be used as a tocolytic agent. If tocolysis is indicated for acute preterm labor, use evidence-based tocolytics (calcium channel blockers, NSAIDs, or beta-agonists) to delay delivery for 48 hours to allow corticosteroid administration 6. For preterm birth prevention in appropriate candidates, use 17OHP-C or vaginal progesterone as per established guidelines, not dydrogesterone.